Vedolizumab in Mild to Moderate Crohn's Disease Patients Naive to Biological Therapy: a Multicentric Observational Study

被引：0

作者：

Dotti, A. Z. ^{[1
]}

Vilela, E. G. ^{[2
]}

Chebli, J. M. F.

Chebli, L. A. ^{[3
]}

Magro, D. O. ^{[3
,4
]}

Steinwurz, F. ^{[5
]}

Argollo, M. ^{[6
]}

Carvalho, N. S. ^{[6
]}

Parente, J. M. L. ^{[7
]}

Parra, R. S. ^{[8
]}

Perin, R. L. ^{[9
]}

Flores, C. ^{[10
]}

Morsoletto, E. M. ^{[11
]}

Ferreira, S. D. C. ^{[12
]}

Ludvig, J. C. ^{[13
]}

Kaiser, R. L., Jr. ^{[14
]}

Queiroz, N. S. F. ^{[15
]}

Faria, M. A. G.

Nicollelli, G. M. ^{[16
]}

Andrade, A. R. ^{[17
]}

Kotze, P. G. ^{[18
]}

机构：

[1] Univ Fed Parana, Gastroenterol, Curitiba, Parana, Brazil

[2] Univ Fed Minas Gerais UFMG, Gastroenterol, Belo Horizonte, MG, Brazil

[3] Univ Fed Juiz Fora, Gastroewnterol, Juiz De Fora, Brazil

[4] Univ Campinas UNICAMP, Colorectal Surg, Campinas, Brazil

[5] Hosp Israelita Albert Einstein, Gastroenterol, Sao Paulo, Brazil

[6] Sao Luiz Hosp, Gastroenterol, Sao Paulo, Brazil

[7] Univ Fed Piaui, Gastroenterol, Teresina, Brazil

[8] Univ Sao Paulo, Colorectal Surg, Ribeirao Preto, Brazil

[9] Univ Passo Fundo, Colorectal Surg, Passo Fundo, RS, Brazil

[10] Inst Aparelho Digestivo, Gastroenterol, Porto Alegre, RS, Brazil

[11] Hosp Sao Vicente, Gastroenterol, Curitiba, Parana, Brazil

[12] Univ Sao Paulo, Gastroenterol, Ribeirao Preto, Brazil

[13] Clin ESADI, Gastroenterol, Blumenau, Brazil

[14] Kaiser Clin, Colorectal Surg, Sao Jose Do Rio Preto, Brazil

[15] Hosp Santa Cruz, Santa Cruz, CA, Brazil

[16] Kaiser Clin, Colorectal Surg, Sao Jose Do Rio Preto, Brazil

[17] Univ Estadual, Gastroenterol, Salvador, Brazil

[18] Pontificia Univ Catolica Parana PUCPR, IBD outpatient Clin, Curitiba, Brazil

来源：

JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P586

引用

页码：714 / 715

页数：2

共 50 条

[1] Vedolizumab in Mild-to-Moderate Crohn's Disease Patients Naive to Biological Therapy: A Multicentric Observational Study
Dotti, Adriana Zanoni
Magro, Daniela Oliveira
Vilela, Eduardo Garcia
Chebli, Julio Maria Fonseca
Chebli, Liliana Andrade
Steinwurz, Flavio
Argollo, Marjorie
Carvalho, Nayara Salgado
Parente, Jose Miguel Luz
Lima, Murilo Moura
Parra, Rogerio Serafim
Perin, Ramir Luan
Flores, Cristina
Morsoletto, Eloa Marussi
Ferreira, Sandro da Costa
Ludvig, Juliano Coelho
Kaiser, Roberto Luiz
Faria, Mikaell Alexandre Gouvea
Nicollelli, Guilherme Mattioli
Andrade, Adriana Ribas
Queiroz, Natalia Sousa Freitas
Kotze, Paulo Gustavo
[J]. CROHNS & COLITIS 360, 2023, 5 (04)
[2] A retrospective observational study on the effectiveness and safety of vedolizumab with or without budesonide induction therapy among patients with moderate-to-severe Crohn's disease
Weisshof, R.
Vavricka, S.
Pouillon, L.
Braegger, F.
Roset, M.
Bent-Ennakhil, N.
Ferrante, M.
[J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S317 - S318
[3] Therapy of mild to moderate colonic Crohn's disease
Akpinar, H. A.
[J]. IBD 2007 - ACHIEVEMENTS IN RESEARCH AND CLINICAL PRACTICE, 2008, 159 : 221 - 231
[4] Therapy of mild to moderate luminal Crohn's disease
Michetti, P
Juillerat, P
Mottet, C
Gonvers, JJ
Burnand, B
Vader, JP
Froehlich, F
Felley, C
[J]. DIGESTION, 2005, 71 (01) : 13 - 18
[5] A PHASE 3 STUDY OF VEDOLIZUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN JAPANESE PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE
Ogata, Haruhiko
Motoya, Satoshi
Watanabe, Kenji
Kanai, Takanori
Matsui, Toshiyuki
Suzuki, Yasuo
Shikamura, Mitsuhiro
Sugiura, Kenkichi
Oda, Kazunori
Hori, Tetsuharu
Araki, Takahiro
Watanabe, Mamoru
Hibi, Toshifumi
[J]. GASTROENTEROLOGY, 2019, 156 (06) : S1109 - S1109
[6] Efficacy of Vedolizumab Therapy in Patients With Perianal Crohn's Disease
Manski, Scott
Edirisuriya, Chelsea
Fabrizio, Joseph
Dioguardi, Vincent
Gandhi, Hema K.
Shivashankar, Raina
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S847 - S848
[7] Effectiveness of Vedolizumab Therapy for Crohn's Disease
Kessing, Richard
[J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2019, 57 (12): : 1443 - 1443
[8] Comparison of Surgical Rates in Biologic Naive Crohn's Disease Patients on Ustekinumab and Vedolizumab
Mohammed, Abdul
Alchirazi, Khaled Alsabbagh
Hamid, Osama
Eltelbany, Ahmed
Garg, Rajat
Paranji, Neethi
Gonzaga, Ernesto Robalino
Singh, Amandeep
Kais, Susan
Regueiro, Miguel
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S706 - S707
[9] Ustekinumab versus Vedolizumab for Moderate to Severe Crohn's Disease
Singh, Amandeep
Khan, Freeha
Lopez, Rocio
Shen, Bo
[J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S393 - S394
[10] Vedolizumab as a rescue therapy for patients with medically refractory Crohn's disease
Crowell, K. T.
Tinsley, A.
Williams, E. D.
Coates, M. D.
Bobb, A.
Koltun, W. A.
Messaris, E.
[J]. COLORECTAL DISEASE, 2018, 20 (10) : 905 - 912

← 1 2 3 4 5 →